Its involvement in human malignant neoplasms underscores its potential therapeutic target for cancer immunotherapy, as it fosters cancer progression, immune escape and therapeutic resistance through TGF-β signaling pathways (Alhossiny et al., 2016). This evidence concerns the gene TGFB1 and cancer.